TauRx Pharmaceuticals Ltd is a biotechnology company focused on developing groundbreaking drugs for the management of neurodegenerative diseases, particularly Alzheimer's Disease and Mild Cognitive Impairment.

Claude Wischik

TauRx Pharmaceuticals Ltd

TauRx was established to address one of the world’s biggest challenges – beating Alzheimer’s disease and other degenerative brain disorders through a completely new approach. A leader in Alzheimer’s research, the company’s mission is to discover, develop and commercialise innovative products for the diagnosis, treatment and cure of neurodegenerative disorders.  

TauRx’s strong research team, supported through cooperative relationships with multiple academic institutions around the world, has focussed on the tau pathway, believed to be one of the critical causes of neurodegeneration in the brain. The company’s novel tau aggregation inhibitors (TAIs) target the formation of tau protein ‘tangles’ in the brain, with its lead compound having shown strong pharmacological effect in early trials for participants with mild and moderate Alzheimer's disease. 

The experimental drug has shown to inhibit aggregation of tau, synuclein, TPD-43 and huntingtin proteins. It is currently in development for the treatment and prevention of Alzheimer’s disease, with a pivotal phase 3 clinical trial in progress and results recently disclosed. 

Additionally, TauRx works closely with joint venture company Genting TauRx Diagnostics Ltd (GTD) in the development of ground-breaking new diagnostic tools and blood tests for dementia, which will help transform the treatment pathway for those affected, ensure efficient and early diagnosis and enhance access to treatment and care.   

TauRx is incorporated in Singapore with primary research and operations in Aberdeen, Scotland.

Dundee Corporation

Arcane Group

Genting management

TauRx

Is there a link between brain injury and Alzheimer’s disease? 

Research* suggests that up to one third of patients with even a single episode of traumatic brain injury develop abnormal tau tangles, which can lead to the development of dementia. 

To learn more about tau and its role in Alzheimer’s disease, follow our page 📲

#TauFact #TauRx #Dementia #Alzheimers 

*Source: Johnson VE, et al (2012) Widespread τ and amyloid-β pathology many years after a single traumatic brain injury in humans. Available in Brain Pathol.

Our core values are at the heart of everything we do. 

Swipe below to learn more about our five values: 

🔑 Hard work
🔑 Honesty 
🔑 Teamwork 
🔑 Loyalty 
🔑 Compassion

Read more about our core values here: https://bit.ly/3GRLTYH

#Values #Teamwork #TeamTauRx

📣 TauRx is sponsoring Dementias London 2024! 

As proud partners, we look forward to connecting with fellow professionals to discuss how we can better diagnose, treat and care for those affected by Alzheimer’s disease and other dementias.

Book your place now: https://lnkd.in/eWxWTiZh

#Dementias24 #TauRx

#TauFact: Whilst tau is a healthy protein naturally found in our brains, it may also play a role in the development of dementia. 

This means tau is an important target for the development of a possible treatment. 

Understand more about the formation of damaging tau tangles in Alzheimer’s disease below.

Learn more about the work we do at www.taurx.com
 
#Dementia #Alzheimers

Did you catch the news? 

🏆 TauRx won the Research and Development Achievement Award at the UK Pharma Industry Awards! 

We’re pleased to be recognised for our dedication to researching and developing an effective tau-targeting treatment for Alzheimer’s disease - helping to address one of the great challenges in the medical field. 

Read more in The Telegraph: https://lnkd.in/eNiuPhhM

#PharmaAwards #ResearchandDevelopment #TauRx

How well do you know tau? 

Today’s #TauFact takes us back to basics, explaining the function of tau protein and how it can misfold and lead to dementia. 

Learn more about how this relates to the work we do at https://lnkd.in/eWD3rB3h

#TheTimeForTauIsNow #Dementia #Alzheimers

The risk of dementia among professional footballers has been reported to be almost four times higher than the general population.  
 
A condition called chronic traumatic encephalopathy, or CTE, is prevalent among former players of high-impact sports and shares many features with Alzheimer’s disease. CTE is also a tauopathy but sees tau proteins malfunction due to brain injury, whereas in Alzheimer’s these changes are often due to other factors linked to aging. 
  
Last year, our Head of Medical Affairs, Dr Sonya Miller, spoke to Psychiatric Times to discuss how possible breakthroughs in treatments for Alzheimer’s could hold the key to a treatment for generations of sports people with CTE as well. Read more here: https://bit.ly/3CpS2JK

#TauRx #CTE #Alzheimers #Dementia

It’s the TauRx mission to develop and commercialise products to treat and diagnose the neurodegenerative diseases caused when the tau protein found naturally in our brains misfolds and aggregates.

Hear from our leadership team on how we’re working to achieve this in the video below and learn more about our work: www.taurx.com

Yesterday, Prof. Linda Sommerlade, Dr Sonya Miller, and Jeffrey LaVaute participated in a panel discussion moderated by Jim Pearson, Deputy Chief Executive from Alzheimer Scotland. 

The panel, “Using the patient and caregiver voice to improve our understanding of their experiences living with Alzheimer’s disease” covered important learnings from TauRx and GT Diagnostics’ patient engagement work in Alzheimer’s.

Are you attending the conference? Make sure to drop by our stand and tell us the key insights you’ve learned in the comments 💡

🏆 TauRx won the Research and Development Achievement Award at the UK Pharma Industry Awards! 

Last month, TauRx was recognised for its continuous and dedicated work to develop an effective tau-targeting treatment for Alzheimer’s disease – one of the world’s most urgent unmet medical needs. 

Congratulations to all of the winners 👏

#PharmaAwards #ResearchAndDevelopment #TauRx

Metric
Company Name	TauRx Pharmaceuticals Ltd
Symbol
MSH ID	COM:TAURX
Market	PRIVATE
Sector	Healthcare
Industry	Biotechnology
Country	GB
Stage
Employee Count	75
Website	taurx.com
LinkedIn	taurx-therapeutics
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	2.02K
Web Traffic Growth	-0.28
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:TAURX

TauRx Pharmaceuticals Ltd

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue